These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 39174596)
1. Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models. Bansal A; Lavoie RR; Lucien F; Kethamreddy M; Wootla B; Dong H; Park SS; Pandey MK Sci Rep; 2024 Aug; 14(1):19561. PubMed ID: 39174596 [TBL] [Abstract][Full Text] [Related]
2. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286 [TBL] [Abstract][Full Text] [Related]
4. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164 [TBL] [Abstract][Full Text] [Related]
5. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025 [TBL] [Abstract][Full Text] [Related]
6. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743 [TBL] [Abstract][Full Text] [Related]
8. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Jiang J; Zhang M; Li G; Liu T; Wan Y; Liu Z; Zhu H; Yang Z Bioorg Med Chem Lett; 2020 Feb; 30(4):126915. PubMed ID: 31926788 [TBL] [Abstract][Full Text] [Related]
10. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors. Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947 [TBL] [Abstract][Full Text] [Related]
11. Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549 [TBL] [Abstract][Full Text] [Related]
13. Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model. Jiang J; Li D; Liu T; Xia L; Guo X; Meng X; Liu F; Wang F; Yang Z; Zhu H Bioorg Med Chem Lett; 2021 May; 40():127901. PubMed ID: 33705912 [TBL] [Abstract][Full Text] [Related]
14. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047 [TBL] [Abstract][Full Text] [Related]
15. ImmunoPET Imaging of α White JB; Hu LY; Boucher DL; Sutcliffe JL Mol Imaging Biol; 2018 Feb; 20(1):103-113. PubMed ID: 28653240 [TBL] [Abstract][Full Text] [Related]
16. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer. Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483 [TBL] [Abstract][Full Text] [Related]
17. In Vivo Imaging of the Programmed Death Ligand 1 by González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151 [TBL] [Abstract][Full Text] [Related]
18. Preclinical development of novel PD-L1 tracers and first-in-human study of [ Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333 [TBL] [Abstract][Full Text] [Related]
19. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027 [TBL] [Abstract][Full Text] [Related]
20. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]